But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in ...

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have ...

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

An FDA pilot program, known as the Commissioner’s Priority Voucher program, could drastically change the way pharmaceutical ...